In conclusion, results from clinical trials such as EMPEROR-Preserved, DELIVER, EMPEROR-Reduced, and DAPA-HF demonstrate that SGLT-2 inhibitors exert broad cardiovascular protective effects in heart failure treatment. Here, SLC5A2 is linked to heart failure.